NASDAQ:HROW Harrow Health - HROW Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Harrow Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $19.24 +0.11 (+0.58%) (As of 02/7/2023 12:00 AM ET) Add Compare Share Share Today's Range$18.15▼$19.3950-Day Range$10.90▼$19.2452-Week Range$5.40▼$19.39Volume526,181 shsAverage Volume258,935 shsMarket Capitalization$520.83 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Harrow Health MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside19.5% Upside$23.00 Price TargetShort InterestBearish4.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.95Based on 2 Articles This WeekInsider TradingAcquiring Shares$393,561 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.66) to $0.14 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector626th out of 1,029 stocksPharmaceutical Preparations Industry306th out of 504 stocks 2.5 Analyst's Opinion Consensus RatingHarrow Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, Harrow Health has a forecasted upside of 19.5% from its current price of $19.24.Amount of Analyst CoverageHarrow Health has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.73% of the float of Harrow Health has been sold short.Short Interest Ratio / Days to CoverHarrow Health has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Harrow Health has recently increased by 0.87%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHarrow Health does not currently pay a dividend.Dividend GrowthHarrow Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HROW. Previous Next 3.3 News and Social Media Coverage News SentimentHarrow Health has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Harrow Health this week, compared to 1 article on an average week.Search Interest13 people have searched for HROW on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harrow Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $393,561.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders14.26% of the stock of Harrow Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.47% of the stock of Harrow Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Harrow Health are expected to grow in the coming year, from ($0.66) to $0.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow Health is -23.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow Health is -23.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow Health has a P/B Ratio of 46.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Harrow Health (NASDAQ:HROW) StockHarrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Read More Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter. Email Address HROW Stock News HeadlinesFebruary 3, 2023 | finance.yahoo.comHarrow (HROW) is on the Move, Here's Why the Trend Could be SustainableFebruary 2, 2023 | finance.yahoo.comHarrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023February 8, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…January 23, 2023 | finance.yahoo.comHarrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired ProductsJanuary 21, 2023 | finance.yahoo.comInvesting in Harrow Health (NASDAQ:HROW) five years ago would have delivered you a 752% gainDecember 25, 2022 | finance.yahoo.comTrade Alert: The CEO & Chairman of the Board Of Harrow Health, Inc. (NASDAQ:HROW), Mark Baum, Has Just Spent US$335k Buying 1.8% More SharesDecember 21, 2022 | finance.yahoo.comMelt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety StudyDecember 15, 2022 | marketwatch.comHarrow Health to Buy U.S. Rights to Novartis Drugs For Up to $175 MillionFebruary 8, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…December 15, 2022 | seekingalpha.comHarrow Health Transaction Moves It Closer To The Big Leagues For 2023November 30, 2022 | finance.yahoo.comHarrow and iOR Partners Expand National Product Supply AgreementNovember 16, 2022 | finance.yahoo.comHarrow Health Third Quarter 2022 Earnings: Misses ExpectationsOctober 28, 2022 | finance.yahoo.comHarrow to Announce Third Quarter 2022 Financial Results on November 14, 2022October 27, 2022 | finance.yahoo.comMelt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300October 13, 2022 | finance.yahoo.comHarrow Health, Inc. (NASDAQ:HROW) has caught the attention of institutional investors who hold a sizeable 48% stakeOctober 6, 2022 | finance.yahoo.comHarrow Health sells part of company for up to $10.5 millionOctober 5, 2022 | finance.yahoo.comHarrow Sells Non-Ophthalmic Compounding BusinessSeptember 29, 2022 | finance.yahoo.comImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic FormulationSeptember 28, 2022 | finance.yahoo.comFDA Approves First Branded Ocular Anesthetic In Almost 14 YearsSeptember 27, 2022 | finance.yahoo.comHarrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface AnesthesiaSeptember 21, 2022 | seekingalpha.comHROW Harrow Health, Inc.September 21, 2022 | finance.yahoo.comMelt Pharmaceuticals files for IPOAugust 27, 2022 | finance.yahoo.comIs Harrow Health (HROW) a Wise Investment Choice?August 19, 2022 | seekingalpha.comSRK Capital - Harrow Health: Market Missing The Forest For The TreesAugust 11, 2022 | finance.yahoo.comHarrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual ConferenceJuly 27, 2022 | finance.yahoo.comHarrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022July 16, 2022 | uk.finance.yahoo.comHarrow Health, Inc. (HROW)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter. Email Address HROW Company Calendar Last Earnings11/14/2022Today2/08/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HROW CUSIPN/A CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees182Year FoundedN/APrice Target and Rating Average Stock Price Forecast$23.00 High Stock Price Forecast$24.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+19.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,010,000.00 Net Margins-25.50% Pretax Margin-25.27% Return on Equity-11.57% Return on Assets-0.79% Debt Debt-to-Equity Ratio83.80 Current Ratio3.49 Quick Ratio3.20 Sales & Book Value Annual Sales$72.48 million Price / Sales7.19 Cash Flow$0.07 per share Price / Cash Flow277.67 Book Value$0.41 per share Price / Book46.93Miscellaneous Outstanding Shares27,070,000Free Float23,213,000Market Cap$520.83 million OptionableOptionable Beta0.22 Key ExecutivesMr. Mark L. Baum J.D. (Age 49)CEO & Chairman Comp: $1.07MMr. Andrew R. Boll C.F.A. (Age 40)C.M.A., CFA, CMA, CFO & Corp. Sec. Comp: $716.73kDr. Robert J. Kammer D.D.S. (Age 73)Special Advisor Comp: $91.88kMr. John P. Saharek MBA (Age 62)Chief Commercial Officer Comp: $621.92kJamie WebbDirector of Communications & Investor RelationsDr. Dennis E Saadeh Pharm.D.Chief of Formulation StrategyMr. Andrew LivingstonChief Innovation OfficerMs. Kim BarrattChief Talent OfficerMore ExecutivesKey CompetitorsADC TherapeuticsNYSE:ADCTConcert PharmaceuticalsNASDAQ:CNCEPrecigenNASDAQ:PGENNGM BiopharmaceuticalsNASDAQ:NGMLexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsiders & InstitutionsB. Riley Securities Inc.Bought 155,825 shares on 2/7/2023Ownership: 0.576%Acuitas Investments LLCSold 99,708 shares on 2/6/2023Ownership: 0.880%Mendota Financial Group LLCBought 19,073 shares on 2/3/2023Ownership: 0.070%Bailard Inc.Bought 11,237 shares on 2/2/2023Ownership: 0.042%Simplex Trading LLCSold 28,200 shares on 2/2/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions HROW Stock - Frequently Asked Questions Should I buy or sell Harrow Health stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HROW shares. View HROW analyst ratings or view top-rated stocks. What is Harrow Health's stock price forecast for 2023? 1 brokerages have issued 12 month target prices for Harrow Health's stock. Their HROW share price forecasts range from $22.00 to $24.00. On average, they predict the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price. View analysts price targets for HROW or view top-rated stocks among Wall Street analysts. How have HROW shares performed in 2023? Harrow Health's stock was trading at $14.76 at the start of the year. Since then, HROW stock has increased by 30.4% and is now trading at $19.24. View the best growth stocks for 2023 here. When is Harrow Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our HROW earnings forecast. How were Harrow Health's earnings last quarter? Harrow Health, Inc. (NASDAQ:HROW) posted its quarterly earnings data on Monday, November, 14th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.02 by $0.08. The firm earned $22.82 million during the quarter, compared to analysts' expectations of $23.39 million. Harrow Health had a negative net margin of 25.50% and a negative trailing twelve-month return on equity of 11.57%. What guidance has Harrow Health issued on next quarter's earnings? Harrow Health issued an update on its FY 2023 earnings guidance on Monday, January, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135.00 million-$143.00 million, compared to the consensus revenue estimate of $117.72 million. What other stocks do shareholders of Harrow Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO). What is Harrow Health's stock symbol? Harrow Health trades on the NASDAQ under the ticker symbol "HROW." Who are Harrow Health's major shareholders? Harrow Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Acuitas Investments LLC (0.88%), Westside Investment Management Inc. (0.70%), B. Riley Securities Inc. (0.58%), Mendota Financial Group LLC (0.07%), Bailard Inc. (0.04%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom. View institutional ownership trends. How do I buy shares of Harrow Health? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Harrow Health's stock price today? One share of HROW stock can currently be purchased for approximately $19.24. How much money does Harrow Health make? Harrow Health (NASDAQ:HROW) has a market capitalization of $520.83 million and generates $72.48 million in revenue each year. The company earns $-18,010,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. How many employees does Harrow Health have? The company employs 182 workers across the globe. How can I contact Harrow Health? Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The official website for the company is www.harrowinc.com. The company can be reached via phone at (615) 733-4730, via email at jwebb@harrowinc.com, or via fax at 858-345-1745. This page (NASDAQ:HROW) was last updated on 2/8/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.